October 2007

IMPORTANT PRESCRIBING INFORMATION

Dear Healthcare Professional:

Amylin Pharmaceuticals, Inc. (Amylin) and Eli Lilly and Company (Lilly) wish to inform you of an important update to the Prescribing Information (PI) for BYETTA® (exenatide) injection, concerning postmarketing reports of acute pancreatitis. Included below are the changes to the Prescribing Information (PI) and additional information concerning those reports.

The prior label dated September 2007 included acute pancreatitis as a postmarketing adverse event. The updated information provides additional guidance regarding symptoms that may be suggestive of acute pancreatitis and subsequent patient management. Specifically, the BYETTA PI has been updated as follows:

Under ***PRECAUTIONS***:

Postmarketing cases of acute pancreatitis have been reported in patients treated with BYETTA. Patients should be informed that persistent severe abdominal pain, which may be accompanied by vomiting, is the hallmark symptom of acute pancreatitis. If pancreatitis is suspected, BYETTA and other potentially suspect drugs should be discontinued, confirmatory tests performed and appropriate treatment initiated. Resuming treatment with BYETTA is not recommended if pancreatitis is confirmed and an alternative etiology for the pancreatitis has not been identified.

Under ***PRECAUTIONS, Information for Patients***:

Patients should be informed that persistent severe abdominal pain, which may be accompanied by vomiting, is the hallmark symptom of acute pancreatitis and be instructed to contact their physician if this symptom occurs (see PRECAUTIONS).

Amylin and Lilly have extensively reviewed all available information and the following is a summary of the most pertinent information:

- Since market introduction in June 2005 through July 2007, over 700,000 patients had been treated with BYETTA. The cumulative spontaneous reporting rate for pancreatitis over this period is 0.20 events per 1000 patient years of exposure. Resolution of pancreatitis was observed with supportive treatment and suspension of suspect medications, including BYETTA.

- Among the reported cases of pancreatitis, a significant proportion of patients had at least one independent risk factor for pancreatitis. Known risk factors of acute pancreatitis include history of pancreatitis, biliary-related complications, severe hypertriglyceridemia, and certain drugs.
- For spontaneous postmarketing reports received since market introduction in June 2005 through July 2007 the time to onset of pancreatitis after initiation of treatment with BYETTA was variable, ranging from 1 day to over 1 year.
- There was no evidence of pancreatitis in the preclinical toxicology studies.
- The incidence of pancreatitis observed during clinical development of BYETTA was lower for exenatide-treated subjects (6 cases; 1.7/1000 subject-years) compared to placebo-treated (1 case; 3.0/1000 subject-years) or insulin-treated subjects (1 case; 2.0/1000 subject-years).
- An epidemiologic study that reviewed data from 2000 to 2005 showed a greater background incidence of acute pancreatitis in patients with type 2 diabetes receiving oral antidiabetic medication compared to a non-diabetic cohort.

While causality cannot be firmly established, an association is suspected. To better understand the relationship, if any, between the use of BYETTA and reports of acute pancreatitis, Amylin and Lilly will continue to carefully monitor such events through ongoing surveillance and analysis, in addition to ongoing epidemiologic investigation.

To report adverse events among patients taking BYETTA, please call 1-800-868-1190. Alternatively, adverse event information may be reported to FDA's MedWatch Reporting System by phone at 1-800-FDA-1088, by facsimile at 1-800-FDA-0178, or by mail using FDA Form 3500 at http://www.fda.gov/medwatch/index.html.

We urge you to contact our Medical Information department at 1-800-868-1190 if you have any questions about the information contained in this letter or the safe and effective use of BYETTA.

Sincerely,

David Maggs, M.D.
Vice President, Medical Affairs
Amylin Pharmaceuticals, Inc.

Timothy Garnett, M.D.
Vice President, Global Patient Safety
Eli Lilly and Company

Enclosure: BYETTA® (exenatide) injection Full Prescribing Information